|
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio). |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - AstraZeneca; Roche; SERVIER |
Consulting or Advisory Role - Celldex; Ipsen; Roche |
Research Funding - Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Aix Venier (Inst) |
Travel, Accommodations, Expenses - SERVIER |
|
|
Honoraria - Abbvie; Bayer; Bracco Diagnostics; Guerbet; Prime Oncology |
Consulting or Advisory Role - Abbvie; Prime Oncology |
Travel, Accommodations, Expenses - Abbvie; Bracco Diagnostics; Guerbet |
|
|
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Mundipharma |
|
|
No Relationships to Disclose |
|
|
Employment - Roche/Genentech |
Honoraria - Roche/Genentech |
|
|
Honoraria - Abbvie; Chugai Pharma; Eisai; MSD |
Consulting or Advisory Role - Novocure; Roche |
Research Funding - Chugai Pharma (Inst); MSD (Inst) |
|
|
Honoraria - Roche/Genentech |
Consulting or Advisory Role - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Roche |
Consulting or Advisory Role - Novartis; Roche |
Speakers' Bureau - Guerbet; Novartis; Roche |
Research Funding - Deutsche Forschungsgemeinschaft (Inst); Roche (Inst) |
|
|
Employment - Roche/Genentech |
Honoraria - Roche/Genentech |
|
Timothy Francis Cloughesy |
Consulting or Advisory Role - Abbvie; Agios; Amgen; Celgene; Celldex; cortice; CytRx Corporation; Lpath; Nektar; NewGen Therapeutics; Novartis; Novocure; Oxigene; proximagen; Roche/Genentech; Stemcycle; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust |
|
|
Honoraria - MSD Oncology; Prime Oncology; Roche/Genentech |
Consulting or Advisory Role - Celldex; Roche/Genentech |
Research Funding - Apogenix (Inst); Boehringer Ingelheim (Inst); Roche (Inst) |